- Mersana Therapeutics is a clinical-stage biopharmaceutical company developing antibody-drug conjugates ("ADCs") for cancer patients.
- Mersana has developed an early-stage pipeline of 8 therapeutic programs with 2 clinical-stage therapeutics in phase 1 (XMT-1536, -1592) expected to progress quickly by FYE 2021.
- Mersana has sustained a stable financial position with FYE 2020's cash ending at approximately $255M, enough to fund operations for 2+ years.
- Mersana has a critical catalyst in 2H 2021 which is XMT-1536's anticipated updated interim phase 1 data from the NSCLC adenocarcinoma expansion cohort.
- In summary, the author projects Mersana Therapeutics as a risky "hold" until 2H 2021 which thereafter may offer +62% upside by FYE 2022.
For further details see:
Mersana: XMT-1536's Complications, New CMO, And 2H 2021's Critical Catalyst